clinical trial · NCT07265947
Phase 2A/B Efficacy and Safety of Dabogratinib in Participants With Low Grade Upper Tract Urothelial Carcinoma
Low Grade Upper Tract Urothelial CarcinomaDabogratinib (TYRA-300) 60mgDabogratinib (TYRA-300) 80mgDabogratinib (TYRA-300) TBD
brief summary
A Phase 2A/B study of Dabogratinib (TYRA-300) in Low Grade Upper Tract Urothelial Carcinoma
started
Dec 22, 2025
primary completion
Oct 1, 2030
completion
Nov 1, 2030
last updated
Jul 1, 2026
detailed description
A Phase 2A/B, Multi-center, Open-Label Study Evaluating the Efficacy and Safety of Dabogratinib (TYRA-300) in Participants with Low Grade Upper Tract Urothelial Carcinoma (SURF303)
official title
A Phase 2A/B, Multi-center, Open-Label Study Evaluating the Efficacy and Safety of Dabogratinib (TYRA-300) in Participants With Low Grade Upper Tract Urothelial Carcinoma (SURF303)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol